enlarged-prostate-bph

The prostate is a walnut-sized, muscular gland surrounding the urethra. The urethra is the tube that allows urine and sperm to pass through the body. An enlarged prostate is a condition in which the prostate gland grows larger and presses on the urethra, leading to urination and bladder problems.

An enlarged prostate is often called Benign Prostatic Hyperplasia (BPH), or Benign Prostatic Hypertrophy. It is not cancer, nor does it raise your risk for prostate cancer. In fact, it is a fairly common condition that occurs in almost all men as they get older.

There are numerous symptoms of an enlarged prostate, some of which include: urinary retention, incomplete emptying of your bladder, incontinence, urinating two or more times per night, pain while urinating or bloody urine, delayed start of the urinary stream, strong and sudden urge to urinate as well as a weak urine stream.

If you are experiencing some of these symptoms or if you would like more information, please visit our Contact page or call us at 239-226-ASAP (2727)

Do You know that doctor Miranda-Sousa is now a certified Urolift provider.

There’s a better option that can help men feel revitalized without having to compromise: The UroLift System treatment. This is typically a one-time, in-office procedure that is a straightforward solution to treat the blockage, freeing men from ongoing BPH medications with a rapid recovery.

Learn More Here

Introducing the next-generation of minimally invasive BPH treatment


The OptilumeÆ BPH Catheter System revolutionizes the treatment paradigm by providing immediate and durable symptom relief for men* experiencing BPH induced lower urinary tract symptoms. (1,2) This minimally invasive surgical therapy combines mechanical dilation with concurrent localized delivery
of paclitaxel for treating BPH. Mechanical dilation with the proprietary double-lobe balloon technology achieves an anterior commissurotomy (split) releasing the constricting lateral lobes, while the delivery of paclitaxel prevents re-fusion of the lobes and maintains patency during healing.

Do you suffer from BPH?

As men* age, it’s common to encounter prostate enlargement, leading to a condition known as benign prostatic hyperplasia (BPH). In fact, BPH affects 70% of men 60-69 years of age and 80% of those 70 years of age or older(1). The prostate surrounds the tube responsible for transporting urine and semen, know as the urethra. With BPH, as the prostate grows larger, it exerts pressure on the urethra, potentially causing interruptions in the natural flow of urine.

Are BPH symptoms disrupting your way of life?

  • Frequent trips to the bathroom, day and night
  • Weak, slow or intermittent flow
  • Urgent need to pee
  • Inability to fully empty bladder

If any of these describe your condition, talk to a Healthcare Provider about your Lower Urinary Tract Symptoms (LUTs). Some Laborie products may not be available in certain regions. Please contact your Healthcare Provider to learn more about the products available to you.

Revolutionizing The Treatment Of BPH

OptilumeÆ BPH Catheter System is a minimally invasive procedure with quick recovery time, and immediate symptom relief that is durable. By combining mechanical dilation of the prostate with concurrent delivery of an anti-mitotic pharmaceutical agent, paclitaxel, your physician can effectively target and treat the cause of your BPH symptoms. After the Optilume Æ BPH procedure, you will notice an immediate improvement in both urinary symptoms and quality of life, including improved urinary flow and the ability to happily relieve your bladder. Clinical studies show significant and durable improvements, allowing you to reclaim control of your urinary system.

Choose the OptilumeÆ BPH Catheter System for immediate, lasting results

  • Clinical studies show OptilumeÆ BPH is safe and effective (3,4)
  • Immediate and durable symptom relief (3,4)
  • Minimal catheter time (3,4)
  • No impact on sexual function (3,4)
  • Quick recovery (3,4)
  • Highest clinically reported flow rates of any minimal invasive therapy (4)
  • Outpatient procedure
  • No cutting, heating, burning, lasering, steaming, or implantation

After the OptilumeÆ BPH procedure you will notice an immediate improvement in both urinary symptoms and quality of life, including improved urinary flow and the ability to happily relieve your bladder. Clinical studies show significant and durable improvements (3,4), allowing you to reclaim control
of your urinary system.

What is the OptilumeÆ BPH Catheter System, and how is it used?

Typically administered as an outpatient procedure, OptilumeÆ BPH is a drug-coated balloon that is inserted into the urethra via a telescopic camera, to the prostate.

Once in the prostate, the balloon expands creating an opening, and releases the safe and proven drug (2), Paclitaxel, into the open prostate.

When the drug coating is fully released, the balloon is deflated and removed. The drug prevents re-fusion of the lobes during healing, keeping the prostate open, restoring the flow of urine and relieving you of your bothersome symptoms.

No cutting. No heating. No burning. No lasering. No steaming. No implantation!

Discover the difference OptilumeÆ BPH can make in restoring your quality of life. Ask your doctor about OptilumeÆ BPH today.

  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474-9. doi: 10.1016/s0022- 5347(17)49698-4. PMID: 6206240.
  2. Kamath KR, Barry JJ, Miller KM. The Taxus™ drug-eluting stent: a new paradigm in controlled drug delivery. Adv Drug Deliv Rev 2006;58:412-36
  3. Kaplan, Steven; Pichardo, Merycarla; Rijo, Edwin; Lay, Ramon Rodriguez; Espino, Gustavo; Estrella, Rafael MP76-02 AT 4 YEARS, OPTILUME BPH HAS THE HIGHEST SUSTAINED IMPROVEMENT IN PEAK FLOW (QMAX) OF ANY MINIMALLY INVASIVE BPH THERAPY, Journal of Urology: April 2023 – Volume 209 – Issue Supplement 4, doi: 10.1097/JU.0000000000003350.02
  4. Kaplan, Steven A.*; Moss, Jared; Freedman, Sheldon; Coutinho, Karl; Wu, Ning; Efros, Mitchell; Elterman, Dean; D’Anna, Richard; Padron, Osvaldo; Robertson, Kaiser J.; Lawindy, Samuel; Mistry, Sandeep; Shore, Neal; Spier, Jeffrey; Kaminetsky, Jed; Mazzarella, Brian; Cahn, David; Jalkut, Mark; Te, Alexis The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia, Journal of Urology: September 2023 – Volume 210 – Issue 3, doi: 10.1097/JU.0000000000003568
  5. The Optilume BPH Catheter System Instructions For Use, 1124-004 rA.

The Optilume BPH Catheter System is indicated for the treatment of obstructive urinary symptoms associated with Benign Prostatic Hyperplasia (BPH) in men ≥ 50 years of age. The Optilume BPH Catheter System is contraindicated for use in: Patients with known hypersensitivity to paclitaxel or structurally related compounds, patients with an active urinary tract infection, patients with an artificial urinary sphincter, or patients with a penile prosthesis. The Optilume BPH DCB contains paclitaxel, a known genotoxic aneugen capable of causing chromosomal abnormalities in sperm. Paclitaxel is present in semen for an extended duration after treatment with Optilume BPH. The risks associated with these paclitaxel concentrations in semen are unknown. The effect of treatment with the Optilume BPH DCB on sperm and spermatogenesis is also unknown. Men should abstain from sex or use barrier contraception (wear a condom) for 30 days post treatment to avoid exposure of sexual partner to paclitaxel. Paclitaxel may still be present at low levels after 30 days. Potential adverse effects after treatment with the Optilume BPH Catheter System are similar to standard cystoscopic procedures and mechanical dilation and include, but are not limited to fever, bleeding, pain, urinary tract infection, false route of the urethra, dysuria, difficult urination, frequency/urgency/irritative urinary symptoms, urinary retention and related symptoms, blood in urine (hematuria), urinary incontinence, urethrorrhagia, blood in semen (hematospermia), ejaculatory dysfunction, bladder perforation, urethral and/or bladder neck strictures, injury or perforation to the urethra, sphincter or prostatic capsule, and inflammation of genitourinary system (prostatitis, orchitis, balanitis)5

*Trans-women, with or without gender reassignment, may have a prostate. If BPH is diagnosed in a trans-woman, this is managed in the same way as for cisgender men.

*List of treatments is not all inclusive.

Optilume Urethral Drug Coated Balloon for the treatment of Anterior Urethral Stricture


The Optilume urethral drug-coated balloon was developed in response to severe patient and physician dissatisfaction with current stricture solutions.

A Cutting Edge Solution to Solve the Dissatisfaction in Current Stricture Solutions

The OptilumeÆ technology combines mechanical dilation for immediate symptomatic relief with local drug delivery to maintain urethral patency. The semi-compliant balloon expands the tissue creating a mechanical balloon dilation effect rupturing the urethral mucosa and allowing direct, circumferential drug delivery to the exposed submucosa through micro-fissures across the length of the stricture. Rapid uptake of the highly lipophilic drug, paclitaxel, limits hyperactive cell proliferation and the fibrotic scar tissue generation that results in stricture recurrence.

Providing Superior Results to Traditional Urethral Stricture Management

By combining simple and effective balloon dilation with localized delivery of a proven antiproliferative drug, the Optilume technology provides superior results vs standard of care endoscopic management.

Some Laborie products may not be available in certain regions. Please contact your local Laborie Sales Representative to learn more about the products available to you.

MKT-00546 [A]

How durable are the outcomes?

At 5 years, durability continued with 73% FFRI* 3, with a 298% increase in Qmax* (Baseline 5mL, 5-year 19.9mL)1 and a 71% decrease in IPSS* (Baseline 22.5, 5-year 7.2).1 Qmax & IPSS are using FCF* rates – Includes worst observed value carried forward for subjects undergoing repeat intervention of the study
stricture (i.e. clinical failures).

Simple | Easily achieve relief

Safe | Proven on a difficult patient population≥

Durable | The breakthrough treatment to break the stricture cycle

For patients who have failed prior endoscopic treatment, today there is Optilume — a breakthrough urethral drug-coated balloon treatment that dilates the urethral lumen and delivers paclitaxel directly to the stricture, significantly reducing the incidence of stricture recurrence.

How Optilume Works

The Optilume procedure is similar to traditional mechanical dilation methods, making it simple to learn and perform. The semi-compliant balloon mechanically dilates and expands the urethral lumen, creating micro-fissures in the urothelium which facilitate circumferential drug delivery across the length of the urethral stricture. By combining simple and effective balloon dilation with localized delivery of a proven antiproliferative drug≤ – The Optilume Urethral Drug Coated Balloon provides long-term relief from stricture recurrence.

Data on file. DSC016-004 rJ Robust I Clinical Study Final Report
Rosenfield K, Jaff MR, White CJ, et al. Trial of Paclitaxel-Coated Balloon for Artery Disease. NEJM
2015;372(2):145-53

Data on file. RP1277-001 rB

Manufactured by Urotronic, Inc. Please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. The Optilume DCB is indicated for use in patients with obstructive urinary symptoms associated with anterior urethral stricture. It is designed to be used in adult males for urethral strictures of ≤3cm in length. The Optilume DCB is contraindicated for patients with known hypersensitivity to paclitaxel or structurally related compounds and patients with urologic implants such as penile implants or artificial urinary sphincters. Paclitaxel may be present in semen after treatment with the Optilume DCB. The risks associated with paclitaxel in semen and the impact on sperm and spermatogenesis are unknown. Men should abstain or use a condom for 30 days and men with partners of child-bearing potential should use highly effective contraceptive and avoid fathering children for 6 months after treatment. Monitor for signs of anaphylaxis or hypersensitivity to paclitaxel. Potential risks can include, but are not limited to, the following: blood in the urine (hematuria), painful urination (dysuria), urinary tract infection (UTI), urinary retention, and stricture recurrence.

*List of treatments is not all inclusive.
232570 – 0